The preliminary data from Arbutus Biopharma's Phase 2a clinical trial suggests that the combination treatment of AB-729 and pegylated interferon alfa-2a is well tolerated and effective in some patients with chronic hepatitis B virus. This positive news could lead to increased investor confidence in the company's pipeline and potential future revenues, resulting in a positive short-term impact on the stock price.